Development and validation of a discriminating in vitro dissolution method for a poorly soluble drug, olmesartan medoxomil: Comparison between commercial tablets

AAPS PharmSciTech

Volumn 11, Issue 2, 2010, Pages 637-644

  Bajerski, Lisiane ^a   Rossi, Rochele Cassanta ^a   Dias, Carolina Lupi ^a   Bergold, Ana Maria ^a   Fröehlich, Pedro Eduardo ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Dissolution kinetic; Dissolution test; LC UV method; Olmesartan medoxomil; UV method

Indexed keywords

OLMESARTAN; IMIDAZOLE DERIVATIVE; TABLET; TETRAZOLE DERIVATIVE;

ACCURACY; ARTICLE; COMPARATIVE STUDY; DRUG RELEASE; DRUG SOLUBILITY; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MATHEMATICAL MODEL; PH; PRIORITY JOURNAL; TABLET; ULTRAVIOLET SPECTROSCOPY; CHEMISTRY; DRUG SCREENING; DRUG STABILITY; EVALUATION STUDY; PHARMACEUTICS; PROCEDURES; SOLUBILITY; VALIDATION STUDY;

DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; IMIDAZOLES; SOLUBILITY; TABLETS; TECHNOLOGY, PHARMACEUTICAL; TETRAZOLES;

EID: 77954816135     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-010-9421-0     Document Type: Article

References (23)

1. Ansari M, Kazemipour M, Talebnia J. The development and validation of a dissolution method for clomipramine solid dosage forms. Dissol Technol. 2004;11:16-24.
2. Abdou HM. Remington: the science and practice of pharmacy. In: Gennaro AR, editors. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 654-66
3. Löbenberg R, Krämer J, Shah MP, Amidon GL, Dressman JB. Dissolution testing as a prognostic tool for oral drug absorption: dissolution behavior of glibenclamide. Pharm Res. 2000;17:439-44.
4. Shah VP, Konecny JJ, Everett RL, McCullough B, Noorizadeh AC, Skelly JP. In vitro dissolution profile of water-insoluble drug dosage forms in the presence of solubilizers. Pharm Res. 1989;6:612-8.
5. Yoshihara K, Gao Y, Shiga H, Wada R, Hisaoka M. Population pharmacokinetics of olmesartan following oral administration of it prodrug, olmesartan medoxomil in healthy volunteers and hypertensive patients. Clin Pharmacokinet. 2005;44:1324-9.
6. Sagirli O, Onal A, Toker SE, Sensoy D. Simultaneous HPLC analysis of olmesartan and hydrochlorothiazide in combined tablets and in vitro dissolution studies. Chromatographia. 2007;66:213-8. doi:10.1365/s10337-007-0304-9. (Pubitemid 47222836)
7. Koike H, Konse T, Sada T, Ikeda T, Hyogo A, Hinman D et al. Olmesartan medoxomil, a novel potent angiotensin II blocker. Annu Rep Sankyo Res Lab. 2003;55:1-91.
8. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutical drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413-20.
9. Bajerski L, Rossi RC, Dias CL, Fröehlich PE, Bergold AM. Stability-indicating LC determination of a new antihypertensive, olmesartan medoxomil in tablets. Chromatographia. 2008;68:991-6. doi:10.1365/s10337-008- 0811-3.
10. Pharmacopeial Forum. Pharmacopeial previews. 2004;30:351-63.
11. Pharmacopeia US. USP 32 NF 27. Rockville: USP; 2009.
12. International Conference on Harmonisation (ICH). ICH harmonized tripartite guideline: validation of analytical procedure Q2A; 1994.
13. International Conference on Harmonisation (ICH). ICH harmonized tripartite guideline: validation of analytical procedure Q2B; 1994.
14. Rowe RC, Sheskey PJ, Welle PJ. Handbook of pharmaceutical excipients. In: Rowe RC, Sheskey PJ, Welle PJ, editors. Washington; 2000.
15. Marques M R C, Brown W. Desenvolvimento e validação de métodos de dissolução para formas farmacȩuticas sólidas orais. Analytica. 2002;1:48-51.
16. Costa P J C. Avaliação in vitro da lioequivalȩncia de formulações farmacȩuticas. Braz J Pharm Sci. 2002;38:141-53.
17. Ferraz HG, Consiglieri VO, Storpirtis S. Avaliação da cinética de dissolução de ampicilina em comprimidos comercializados no Brasil. Braz J Pharm Sci. 1998;34:93-109.
18. Costa P, Lobo J M S. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13:123-33.
19. Khan M Z I. Dissolution testing for sustained or controlled release oral dosage forms and correlation with in vivo data: challenges and opportunities. Int J Pharm. 1996;140:131-43.
20. Brown CK, Chokshi HP, Nicherson B, Reed RA, Rohrs BR, Shah PA. Acceptable analytical practices of dissolution testing of poorly soluble compounds. Pharm Technol. 2004;56-65.
21. Rohrs BR. Dissolution method development for poorly soluble compounds. Dissol Technol. 2001;8:1-5.
22. Swanepoel E, Liebenberg W, Devarakonda B, Villiers MM. Developing a discriminating dissolution test for three mebendazole polymorphs based on solubility differences. Pharmazie. 2003;58:117-21.
23. Food and Drugs Administration (FDA). FDA guidance for industry: dissolution testing of immediate release solid oral dosage forms. Rockville: FDA; 1997.